The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

A 2010 study examined three randomized controlled trials involving 78 people with symptomatic diabetic peripheral neuropathy. Researchers found that average pain scores were significantly reduced ...

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

There are over 100 different kinds of peripheral neuropathy, most of which are polyneuropathies. Risk factors and causes of polyneuropathy can include diabetes, alcohol misuse, and certain ...

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

The following is a summary of “Correlation between high-sensitivity cardiac troponin levels in diabetic patients’ serum and ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.